Revised international staging system allocation in the ICARIA-MM study: Practical challenges and impact on outcome

[摘要] The aim of the ICARIA-MM Phase 3 study (ClinicalTrials.gov, numberNCT02990338) was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone comparedwith pomalidomide and dexamethasone alone in patients with relapsedand refractory multiple myeloma [1]. Results from this study demonstrated that the addition of isatuximab to pomalidomide and dexamethasone provides a significant benefit for progression-free survivalover pomalidomide and dexamethasone alone. Additionally, resultsshowed a positive treatment effect in all subgroups, including revisedinternational staging system (R-ISS) stage at study entry [1].